## Title: Humoral waning kinetics against SARS-CoV-2 is dictated by disease severity and vaccine platform

**Authors:** Xin Tong,<sup>1†</sup> Benjamin Kellman,<sup>1†</sup> Maria-Jose Avendano,<sup>2,†</sup> Maanasa Mendu,<sup>1</sup> Jeff C. Hsiao,<sup>1,8</sup> Eileen Serrano,<sup>2</sup> Tamara Garcia-Salum,<sup>2,3,4</sup> Nicolas Muena,<sup>5</sup> Catalina Pardo-Roa,<sup>2,4,6</sup> Mauricio Morales,<sup>3</sup> Jorge Levican,<sup>2</sup> Erick Salinas,<sup>2</sup> Simone Cardenas-Cáceres,<sup>5</sup> Arnoldo Riquelme,<sup>7</sup> Nicole D. Tischler,<sup>5,8</sup> Douglas A. Lauffenburger,<sup>9</sup> Galit Alter,<sup>1</sup> Ryan P. McNamara,<sup>1</sup> Rafael A. Medina,<sup>2,3,4,10</sup>

## Affiliations:

<sup>1</sup> Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA

<sup>2</sup> Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA 30322, USA

<sup>3</sup> Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile

<sup>4</sup> Advanced Interdisciplinary Rehabilitation Register (AIRR) - COVID-19 Working Group, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile

<sup>5</sup> Laboratorio de Virología Molecular, Fundación Ciencia and Vida, Santiago 8581151, Chile

<sup>6</sup> Department of Child and Adolescent Health, School of Nursing, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile

<sup>7</sup> Department of Gastroenterology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago 8331010, Chile

<sup>8</sup> Escuela de Bioquímica, Facultad de Salud y Ciencia, Universidad San Sebastián, Santiago 7510156, Chile.

<sup>9</sup> Department of Biological Engineering, Massachusetts Institute of Technology, Massachusetts, MA, 02139, USA

<sup>10</sup>Center for Research on Influenza Pathogenesis and Transmission (CRIPT) Center of Excellence of Influenza Research and Response (CEIRR), New York, New York, USA

<sup>†</sup>These authors contributed equally

\*Corresponding authors: Ryan McNamara (RPMCNAMARA@mgh.harvard.edu), Rafael A.

Medina (rafael.medina@emory.edu)

## Supplementary Material

Contains Tables S1-S2

Contains Figs S1-S8 and corresponding figure captions

## Supplementary Table S1. Demographic and baseline characteristics of the cohort.

	Outpatients (a) (n = 41)	Hospitalized (b) (n = 36)	CoronaVa c (c) (n = 34)	BNT162b2 (d) (n = 15)	P value*	P value <sup>#</sup>	Outpatients CoronaVac (n = 26)	Hospitalized CoronaVac (n = 16)	P value^	Outpatients BNT162b2 (n = 3)	Hospitalized BNT162b2 (n = 2)	P value^
Characteristics												
Male, n (%)	21 (51.2)	25 (69.4)	10 (29.4)	3 (20.0)	0.0010	0.010 (b,c) 0.011 (b,d)	11 (42.3)	10 (62.5)	0.3408	1 (33.3)	1 (50)	1
Age, median (IQR)	32 (40-26)	53.5 (62.5-37.0)	33 (44-27.25)	36 (38.5-24.5)	< 0.0001	0.0002 (a,b) 0.0009 (b,c) 0.0040 (b,d)	33 (54.75-27.75)	53.5 (62.5-37)	0.0295	27 (28.5-20)	55 (58.5-51-5)	0.1489
> 60 years, n (%)	4 (9.8)	12 (33.3)	1 (2.9)	0 (0)	0.0007	0.0083 (b,c)	3 (11.5)	5 (31.3)	0.2233	0 (0)	1 (50)	0.4
<b>Comorbidities or conditions</b>												
Obesity (BMI $\geq$ 30), n (%)	5 (12.2)	13 (36.1)	5 (14.7)	3 (20)	0.0613	NS	2 (7.7)	7 (43.8)	0.0161	1 (33.3)	1 (50)	1
Hypertension, n (%)	3 (7.3)	12 (33.3)	3 (8.8)	2 (13.3)	0.0119	0.047 (a,b)	3 (11.5)	6 (37,5)	0.0628	0 (0)	0 (0)	NA
Cardiovascular disease, n (%)	0 (0)	3 (8.3)	0 (0)	0 (0)	0.0774	NS	0 (0)	1 (6.3)	0.3810	0 (0)	0 (0)	NA
Chronic pulmonary disease, n (%)	6 (14.6)	3 (8.3)	0 (0)	0 (0)	0.0623	NS	4 (15.4)	1 (6.3)	0.6332	1 (33.3)	0 (0)	1
Asthma, n (%)	8 (19.5)	2 (5.6)	4 (11.8)	4 (26.7)	0.1310	NS	6 (23.1)	0 (0)	0.0671	1 (33.3)	0 (0)	1
Rheumatologic disease, n (%)	0 (0)	2 (5.6)	0 (0)	1 (6.7)	0.1327	NS	0 (0)	1 (6.3)	0.3810	0 (0)	0 (0)	NA
Immunocompromise, n (%)	0 (0)	5 (13.9)	0 (0)	0 (0)	0.0069	NS	0 (0)	3 (18.8)	0.0488	0 (0)	0 (0)	NA
Allergy <sup>+</sup> , n (%)	20 (48.8)	6 (16.7)	17 (50)	6 (40)	0.0089	0.023 (a,b) 0.028 (b,c)	12 (46.2)	2 (12.5)	0.0420	3 (100)	0 (0)	0.1
Neurologic disease, n (%)	0 (0)	4 (11.1)	0 (0)	0 (0)	0.0217	NS	0 (0)	2 (12.5)	0.1394	0 (0)	0 (0)	NA
Smoker, n (%)	6 (14.6)	9 (25.0)	5 (14.7)	4 (26.7)	0.4962	NS	4 (15.4)	4 (25)	0.4538	1 (33.3)	0 (0)	1
Previous treatment												
Immunosuppressive drugs, n (%)	0 (0)	5 (13.9)	0 (0)	0 (0)	0.0071	NS	0 (0)	3 (18.8)	0.0488	0 (0)	0 (0)	NA
Symptoms												
Respiratory												
Cough, n (%)	28 (68.3)	30 (83.3)	NA	NA	0	.1855	19 (73.1)	13 (81.3)	0.7152	3 (100)	2 (100)	NA
Dyspnea, n (%)	7 (17.1)	19 (52.8)	NA	NA	0	.0015	6 (23.1)	11 (68.8)	0.0084	1 (33.3)	2 (100)	0.4
Odynophagia, n (%)	21 (51.2)	6 (16.7)	NA	NA	0	.0019	15 (57.7)	2 (12.5)	0.0045	1 (33.3)	0 (0)	1
Constitutional												
Fever, n (%)	22 (53.7)	30 (83.3)	NA	NA	0	.0073	14 (53.8)	14 (87.5)	0.0420	1 (33.3)	2 (100)	0.4
Headache, n (%)	34 (82.9)	13 (36.1)	NA	NA	<	0.0001	23 (88.5)	5 (31.3)	0.0004	2 (66.7)	2 (100)	1
Myalgia, n (%)	26 (63.4)	17 (47.2)	NA	NA	0	.1742	16 (61.5)	9 (56.3)	0.7570	3 (100)	0 (0)	0.1
Severe fatigue, n (%)	0 (0)	21 (58.3)	NA	NA	<	0.0001	0 (0)	11 (68.8)	< 0.0001	0 (0)	1 (50)	0.4
Altered mental status, n (%)	0 (0)	3 (8.3)	NA	NA	0	.0976	0 (0)	1 (6.3)	0.3810	0 (0)	0 (0)	NA

Abbreviations: IQR, interquartile range; NA, not applicable; NS, not statistically significant. <sup>+</sup> Allergy considered self-reported allergic rhinitis (by seasonal, perennial/year-round, or episodic allergens) and food allergy. Categorical variables compared using Fisher-Freeman-Halton's exact test<sup>\*</sup>; Pairwise Fisher's exact test<sup>#</sup>; Fisher's exact test<sup>^</sup>. Continuous variables compared using Kruskal-Wallis test<sup>\*</sup>; Wilcoxon Rank Sum<sup>#</sup>.

<b>REAGENT or RESOURCE</b>	SOURCE	IDENTIFIER
Anti-Human IgG1-PE	Southern Biotech	HP6001
Anti-human IgG2-PE	Southern Biotech	31-7-4
Anti-human IgG3-PE	Southern Biotech	HP6050
Anti-human IgG4-PE	Southern Biotech	HP6025
Anti-human IgM-PE	Southern Biotech	SA-DA4
Anti-human IgA1-PE	Southern Biotech	HP6025
Human FcyRIIA	Duke Human Vaccine	Custom Order
	Institute	
Human FcyRIIB	Duke Human Vaccine	Custom Order
	Institute	
Human FcyRIIIAV	Duke Human Vaccine	Custom Order
	Institute	
Human FcyRIIIB	Duke Human Vaccine	Custom Order
	Institute	
Anti-CD66b Pac Blue	BioLegend	305112
SARS-CoV-2 WT S1	Sino Biological	40591-V08H
SARS-CoV-2 WT S2	Sino Biological	40590-V08B
SARS-CoV-2 WT Spike	Sino Biological	40589-V08H4
SARS-CoV-2 WT NTD	Sino Biological	40591-V49H
SARS-CoV-2 WT Receptor Binding	Sino Biological	40592-V08H
Domain (RBD)		
SARS-CoV-2 Alpha Variant S	Sino Biological	40589-V08B6
SARS-CoV-2 Alpha Variant RBD	Sino Biological	40592-V08H82
SARS-CoV-2 Beta Variant S	Sino Biological	40589-V08B7
SARS-CoV-2 Beta Variant RBD	Sino Biological	40592-V08H59
SARS-Cov-2 Gamma Variant S	Sino Biological	40589-V08B10
SARS-CoV-2 Gamma Variant RBD	Sino Biological	40592-V08H86
SARS-Cov-2 Delta Variant S	Sino Biological	40589-V08B16
SARS-Cov-2 Delta variant KBD	Sino Biological	40592-V08H115
SARS-Cov-2 Unicron variant S	Sino Biological	40389-V08H20
SARS-COV-2 Nucleocapsia	Sino Biological	40388-V08B 40502 V08H121
Human Coronavirus OC43 S	Sino Diological	40392-V001121 40607 V09D
Human CoV HKU1 S (isolato N5)	Sino Biological	4000/-V08D 40606 V08P
DE Strontovidin	A gilant Tashnalagias	40000 - 0000
NHS Sulfo I C I C Kit	ThermoFisher	7D32-10 21/25
7ahra-Snin Decalting and	ThermoFisher	21733
Chromatography Columns		07002
Green Fluorescent Neutravidin	ThermoFisher	F8776
Microsnheres		10//0
Red Fluorescent Neutravidin	ThermoFisher	F8775
Microsnheres		10//5
when ospher es		

Supplementary Table 2. List of reagents and resources used in this study.

MagPlex Microspheres	Luminex MFG	MC12001-01
		(Cataloged by
		region)
THP-1 Monocytes	ATCC	CVCL_0006
384-well HydroSpeed Plate Washer	Tecan	30190112
iQue Screener Plus	Intellicyt/Sartorius	11811
iQue Forecyt	Sartorius	60028
Vero E6 cells	ATCC	CRL-1586, RRID:
		CVCL_0574
MEM	Gibco	11095-080
FBS	Gibco	16000-044
pCEP4-myc-ACE2	Addgene	141185
Hygromycin	Invitrogen	10687010
<b>Optical bottom 96-well plates</b>	Thermo Scientific	165305
Formaldehyde	Pierce	28906
4',6-diamidino-2-phenylindole (DAPI)	Invitrogen	D1306
R Studio V 1.4.1103	RStudio, PBC	Open Source
GraphPad Prism	GraphPad Software, LLC	Ragon Site License
FlowJo V. 10.8	FlowJo, LLC	www.flowjo.com/s olutions/flowjo/do wnloads



Supplemental FigS1. WT Spike subdomain-specific MFI decay over time post-infection or vaccination for Immunoglobulin and Fc $\gamma$ R. (A, B) Scatter plots show subject-specific (line color) decline in immunoglobulin response and Fc $\gamma$ R binding specific to WT Spike subdomains. Log-linear mixed-effect models with subject-specific random intercepts and slopes estimated trend-lines and 95% confidence intervals using data from subjects following the second BNT162b2 dose (dark-violet), second CoronaVac dose (light-blue), Hospitalized individuals (dark-purple), or Outpatient (light-pink). Horizontal grey lines indicate the innate Spike reactivity in Naïve (no-exposure) samples. Color legend shown at bottom for each panel. (C) Regression intercepts and slopes, indicating initial response and decay rate, are plotted with 95% confidence intervals for by each Spike subdomain. Decay and response parameters across variants (shapes) are stratified by infection/vaccination type (color and shape). Shaded out regions indicate a response < the 97.5<sup>th</sup> percentile of the naïve response. Y-axis units are MFI fold difference respect to the Naïve group.



Halflife

Supplemental FigS2. Spike-specific MFI decay across VOC over time post-infection or vaccination for Immunoglobulin and FcR. (A, B) Scatter plots show subject-specific (line color) decline in immunoglobulin response and FcR binding specific to various VOC Spikes. Log-linear mixed-effect models with subject-specific random intercepts and slopes estimated trend-lines and 95% confidence intervals using data from subjects following the second BNT162b2 (dark-violet), dose, second CoronaVac dose (light-blue), Hospitalized individuals (dark-purple), or Outpatient (light-pink). Horizontal grey lines indicate the innate Spike reactivity in Naïve (no-exposure) samples. Color legend shown at bottom for each panel. (C) Regression intercepts and slopes, indicating initial response and decay rate, are plotted with 95% confidence intervals for by each Spike subdomain. Decay and response parameters across variants (shapes) are stratified by infection/vaccination type (color and shape). Shaded out regions indicate a response < the 97.5<sup>th</sup> percentile of the naïve response. Y-axis units are MFI fold difference respect to the Naïve group.



Supplemental FigS3. RBD-specific MFI decay across VOC over time post-infection or vaccination for Immunoglobulin and FcR. (A,B) Scatter plots show subject-specific (line color) decline in immunoglobulin response and FcR binding specific to various VOC RBDs. Log-linear mixed-effect models with subject-specific random intercepts and slopes estimated trend-lines and 95% confidence intervals using data from subjects following the second BNT162b2 (dark-violet), dose, second CoronaVac dose (light-blue), Hospitalized individuals (dark-purple), or Outpatient (light-pink). Horizontal grey lines indicate the innate spike reactivity in Naïve (no-exposure) samples. Color legend shown at bottom for each panel. (C) Regression intercepts and slopes, indicating initial response and decay rate, are plotted with 95% confidence intervals for by each Spike subdomain. Decay and response parameters across variants (shapes) are stratified by infection/vaccination type (color and shape). Shaded out regions indicate a response < the 97.5<sup>th</sup> percentile of the naïve response. Y-axis units are MFI fold difference respect to the Naïve group.



Supplemental FigS4. Time to decay calculated from the log-linear regression models. Pointranges display the predicted decay periods over which each inoculation- or infection-induced initial response to corresponding naïve (no-exposure) response; the range corresponds to the time predicted for each model to reach the 97.5<sup>th</sup>, 50<sup>th</sup>, and 2.5<sup>th</sup> percentile of the naïve response distribution s.t. Time = (Naïve<sub>97.5th</sub>, 50th, 2.5th – Decay)/Initial. Color legend for group is shown on the right.



**Supplemental FigS5.** Comparison of the peak response post-infection to the peak response following post-infection across VOC for Immunoglobulin and FcR. Paired t-tests are visualized for various VOC Spikes binding (A, B) for naturally infected individuals (hospitalized or outpatients) immunized with either the CoronaVac or BNT162b2 vaccines post-infection. The infection-only boxplots (Out or Hosp) represent the fully waned response (response at the farthest timepoint following infection) while the paired post-infection vaccination boxplots represent peak immunity following vaccination. The grey line indicates the 97th percentile of naïve response. Q-values indicate the FDR corrected significance for each corresponding paired t-test. Y-axis units for A and B are MFI fold difference respect to the Naïve group.



**Supplemental FigS6. Hybrid boosting expands binding breadth for both outpatient and hospitalized recoverees.** Point-ranges indicating the lowest response observed post-infection (circle/square) and the increase in response observed post-vaccination (line height) where response is log10(MFI/MFI\_naive). Plots are stratified by assay, antigen, and VOC and colored by infection and vaccination type. Point-ranges are transparent if a multiple test corrected paired t-test on response is not significant (FDR>0.1). An opaque diamond is added above each point-range if the waned response is less than naïve, the boosted response is greater than naïve, and the multiple test corrected paired t-test is significant. Color legend for group is shown on the right. Y-axis units are MFI fold difference.



**Supplemental FigS7. Comparison of the peak response post-infection to the peak response following post-infection.** Violin plots comparing the immune response (MFI/MFI\_naive) to Omicron and WT Spike binding and function given either CoronaVac or Pfizer vaccination post-infection. (a) Violin plots compare the peak response post-infection to the peak response following post-infection vaccination. Q-values indicate the FDR corrected significance for each corresponding t-test.



**Supplemental FigS8. Comparison of waning with peak response following post-infection boosting.** Violin plots comparing the immune response (MFI/MFI\_naive) to Omicron and WT Spike binding and function given either CoronaVac or Pfizer vaccination post-infection. Violin plots compare waning with peak response following post-infection boosting. The infection-only boxplots (Out or Hosp) represent the fully waned response (response at the farthest timepoint following infection) while the paired post-infection vaccination boxplots represent peak immunity following vaccination. Q-values indicate the FDR corrected significance for each corresponding t-test.